Close X
Tuesday, November 5, 2024
ADVT 
National

A look at the rare blood clot condition VIPIT

Darpan News Desk The Canadian Press, 29 Mar, 2021 08:56 PM
  • A look at the rare blood clot condition VIPIT

Federal officials limited the use of Oxford-AstraZeneca's COVID-19 vaccine Monday while it announced an investigation into reported links to a rare blood clot condition known as VIPIT.

The National Advisory Committee on Immunization says the vaccine should not be used by people younger than age of 55, while Health Canada has issued guidelines around what to look for if you suspect you have had an adverse reaction.

Here’s a look at this rare condition.

WHAT IS VIPIT?

VIPIT stands for: Vaccine-Induced Prothrombotic Immune Thrombocytopenia. According to NACI, it is associated with the development of antibodies that "activate" platelets, which stimulate the formation of blood clots.

HOW DANGEROUS IS VIPIT?

The case fatality of VIPIT is approximately 40 per cent, however that may decrease with increased awareness and early treatment.

HOW COMMON IS THIS ADVERSE REACTION?

It’s not clear how common this happens after vaccination but the European Medicines Agency said March 18 it was originally believed to occur once per 1,000,000 people vaccinated with the AstraZeneca vaccine. However, a higher rate of 1 per 100,000 was reported in Germany.

WHO DOES THIS AFFECT?

So far, cases have largely been among women younger than age 55 and mostly emerged between four and 16 days after vaccination. However, a brief for Ontario’s COVID-19 advisory group notes many European countries used more of their initial AstraZeneca doses in women under age 55, which may have skewed the results.

The provincial science table experts add that VIPIT does not appear to be more common in people who have had blood clots before, have a family history of blood clots, have a low platelets, or pregnant women.

ARE THERE KNOWN CASES IN CANADA LINKED TO THE ASTRAZENECA VACCINE?

No.

WHAT ARE THE WARNING SIGNS?

Experts say to look for the following symptoms between four and 20 days after vaccination: a severe headache that does not go away; a seizure; difficulty moving part of your body; new blurry vision that does not go away; difficulty speaking; shortness of breath; chest pain; severe abdominal pain; new severe swelling, pain, or colour change of an arm or a leg.

MORE National ARTICLES

Liberals want more diverse public service

Liberals want more diverse public service
They also plan to do further research on the makeup of the federal public service and will try to hire more senior leaders with varied backgrounds.

Liberals want more diverse public service

ICBC unveils online tool to estimate car insurance

ICBC unveils online tool to estimate car insurance
Mike Farnworth says the tool allows drivers to estimate their savings once a new model of delivering auto insurance comes into effect at the Crown corporation on May 1.

ICBC unveils online tool to estimate car insurance

Plea set for accused man in Rideau Hall incident

Plea set for accused man in Rideau Hall incident
Hurren allegedly drove a truck onto the grounds of the official residence July 2 and set out on foot toward the house where the prime minister lives.

Plea set for accused man in Rideau Hall incident

Trudeau urges Canadians to cancel travel plans

Trudeau urges Canadians to cancel travel plans
Canada has had a ban on non-essential travel into the country by anyone who isn't a citizen or permanent resident since last March but it can't as easily bar the flow of Canadians in and out of the country.

Trudeau urges Canadians to cancel travel plans

Allegedly flying to Yukon 'despicable': minister

Allegedly flying to Yukon 'despicable': minister
The allegations against them have not been proven in court and the tickets indicate the couple can challenge them.

Allegedly flying to Yukon 'despicable': minister

Bill Morneau drops out of OECD campaign

Bill Morneau drops out of OECD campaign
In a statement on Twitter today, Morneau says he did not have enough support from member countries to make it to the third round of the campaign.

Bill Morneau drops out of OECD campaign